| Document |
Document Title |
|
WO/2022/170122A1 |
The present disclosure relates compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, ...
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/167631A1 |
The invention provides novel heteroaryl-substituted imidazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1 to R6 are as described herein. Further provided are pharmaceutical ...
|
|
WO/2022/162471A1 |
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
|
|
WO/2022/161496A1 |
The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein variables are as defined as set forth in the specification. The present disclosure also provides compound...
|
|
WO/2022/158442A1 |
The present invention provides, as a radioactive halogen-labeled precursor compound that is highly stable and reactive, a compound represented by general formula (II) [in the formula, R1 and R2 each independently represent an alkyl group...
|
|
WO/2022/157499A1 |
The invention relates to protected HDAC inhibitor compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are as defined herein. In aspects, the inventions relates to use of the compounds, and to methods of deprotecting the compounds.
|
|
WO/2022/150174A1 |
The present invention provides for compounds of Formula (I) (I) wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of...
|
|
WO/2022/148717A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
|
|
WO/2022/139179A1 |
The present invention provides a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/138735A1 |
Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant di...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/135136A1 |
Provided herein are tuberculatin analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
|
|
WO/2022/133027A1 |
Compounds of formula (1) wherein R1 represents a -C(R2)(R3)-[C(R4)(R5)]m-L-R6 group or -R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment o...
|
|
WO/2022/131546A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2022/133031A1 |
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
|
|
WO/2022/124499A1 |
The present specification pertains to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2022/117445A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
|
WO/2022/112345A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/112352A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/114164A1 |
Provided is a compound which is useful as an active ingredient for a pharmaceutical composition for treating cancer associated with the activation of an immunocyte or cancer having resistance to an anti-PD-1 antibody/anti-PD-L1 antibody ...
|
|
WO/2022/114444A1 |
The present invention relates to a novel heterocyclic compound usable in an organic light-emitting device and to an organic light-emitting device comprising same, wherein [chemical formula A] and [chemical formula B] are as described in ...
|
|
WO/2022/108259A1 |
The present specification provides a compound of formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/108068A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/107144A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a disorder associated with binding of IGF2BP1 to an RNA in a subject in need thereof ...
|
|
WO/2022/108258A1 |
The present specification provides a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/105845A1 |
A glucoside derivative, and a preparation method therefor and an application thereof. Specifically, provided is a glucoside derivative, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The ...
|
|
WO/2022/106375A1 |
The present invention provides novel compounds having the general formula (I) wherein A, L, and B are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/105852A1 |
Provided are a triazine dione derivative, a preparation method therefor and an application thereof in medicine. Specifically, provided are a triazine dione derivative represented by general formula (I), a preparation method therefor, a p...
|
|
WO/2022/108141A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/099810A1 |
A tetraphenylethylene compound, an application thereof, and an electronic device using same. The structural general formula of the tetraphenylethylene compound is shown in formula 1. The tetraphenylethylene compound contains an aromatic ...
|
|
WO/2022/094355A1 |
The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of prep...
|
|
WO/2022/093748A1 |
This invention relates to processes for making bio-based renewable oils from non-food biomass sources. Such renewable oils are used for cosmetics formulations. More specifically, disclosed are processes of preparation of furan-based comp...
|
|
WO/2022/094354A1 |
The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of prep...
|
|
WO/2022/080765A1 |
The present invention relates to a skin whitening composition comprising a dihydrofuran-2(3H)-one derivative having melanogenesis inhibition and melanosome decomposition activity, an isomer thereof, or a pharmaceutically acceptable salt ...
|
|
WO/2022/073969A1 |
The present invention relates to compounds of Formula (I), wherein Ar1, A, B, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceut...
|
|
WO/2022/060020A1 |
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light-...
|
|
WO/2022/053628A1 |
The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the ...
|
|
WO/2022/053013A1 |
Disclosed in the present invention are a compound represented by formula Ib or IIb, a cis or trans isomer, enantiomer, diastereomer, racemate, tautomer, solvate, hydrate, and pharmaceutically acceptable salt thereof, or a mixture thereof...
|
|
WO/2022/050533A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2022/050592A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting element comprising same.
|
|
WO/2022/047014A1 |
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...
|
|
WO/2022/042299A1 |
A method for extracting mupirocin. The main steps thereof comprise: resin adsorption, desorption and concentration, multi-step extraction, and dehydration and decoloration, wherein the multi-step extraction comprises at least one ester s...
|
|
WO/2022/040788A1 |
Anti -cancer, chemotherapeutic, or antiproliferative compositions comprising, as an active ingredient, a compound of formula (I0), or a salt, or prodrug thereof: and an anti-cancer, chemotherapeutic, or antiproliferative compound (A) or ...
|
|
WO/2022/045618A1 |
Provided is a tertiary amine derivative, which effectively absorbs high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contributes to a substantia...
|
|
WO/2022/034203A1 |
The present invention provides, inter alia, a process for producing a compound of formula (I) wherein the substituents are as defined in claim 1. The present invention further provides intermediate compounds utilised in said process, and...
|
|
WO/2022/033380A1 |
The present invention relates to the technical of medicinal chemistry, and specifically relates to a use of a 6-oxaspiro[4.5] decane derivative as an MOR receptor agonist for treating pain and pain-related disorders.
|
|
WO/2022/031735A1 |
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods o...
|
|
WO/2022/031736A1 |
This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
|
|
WO/2022/028507A1 |
A heterocyclic compound as represented by formula I, a preparation method therefor, a pharmaceutical composition comprising same and use thereof. The heterocyclic compound can be used as a complement factor B inhibitor, and is used for p...
|
